Welcome to our dedicated page for Orthofix Med news (Ticker: OFIX), a resource for investors and traders seeking the latest updates and insights on Orthofix Med stock.
Orthofix Medical Inc. (NASDAQ: OFIX) is a global medical technology company headquartered in Lewisville, Texas, with a focus on musculoskeletal care. The Orthofix news stream highlights developments across its spinal hardware, bone growth therapies, specialized orthopedic solutions, biologics and enabling technologies, including updates related to the 7D FLASH™ Navigation System.
Investors and healthcare professionals following Orthofix news can review regular earnings announcements, where the company reports net sales and segment performance for Bone Growth Therapies, Spinal Implants, Biologics and Enabling Technologies, Global Spine and Global Orthopedics. These releases often include commentary on trends in U.S. Spine Fixation, bone growth therapy performance, and the progress of its orthopedics business focused on limb reconstruction.
News coverage also features regulatory and product milestones, such as FDA 510(k) clearance and CE Mark for the TrueLok™ Elevate Transverse Bone Transport System and the global commercial launch of TrueLok Elevate. Orthofix uses these announcements to describe how TrueLok Elevate fits into its TrueLok family of multiplanar external fixators and supports limb preservation and diabetic wound-related treatment needs.
In addition, Orthofix issues releases about upcoming investor conference appearances and the timing of quarterly financial results and conference calls. For anyone tracking OFIX, this news page provides a centralized view of the company’s public communications on financial performance, product launches, regulatory clearances and investor events.
Orthofix Medical Inc (NASDAQ:OFIX) announced that its Fitbone™ TAA intramedullary limb-lengthening system has surpassed 5,000 implants, with over 20 years of clinical safety and efficacy evidence. This system addresses limb length discrepancies through a minimally invasive procedure. The Fitbone system is available in the U.S. under FDA 510(k) clearance and holds a pediatric indication, making it unique in the market. Orthofix is positioned as a leader in internal and external fixation solutions for limb reconstruction, targeting innovative treatment options for patients with deformities.
The merger of Orthofix Medical and SeaSpine Holdings became effective on January 5, 2023. For Q4 2022, Orthofix reported net sales of $122.2 million, a 2% decline year-over-year, with Bone Growth Therapies growing by 3%. SeaSpine's net sales rose 14% to $63.4 million, buoyed by a strong performance in U.S. Spinal Implants and Orthobiologics, which experienced growth of 23% and 20%, respectively. The merger aims to create synergies, although initial revenue guidance for 2023 reflects minimal impact from these synergies. Orthofix's net loss for Q4 was $(7.1) million, while SeaSpine's net loss stood at $(19.0) million.
Orthofix Medical Inc. (NASDAQ:OFIX) announced an Analyst Teach-In Meeting in Lewisville, TX, on March 13, 2023, from 2:30 to approximately 6:30 p.m. CT. The C-Suite management team will detail the product portfolio and commercial strategy following the merger with SeaSpine. The event has limited in-person attendance, but a live and archived webcast will be available on the company's investor page. The merged entity offers a broad range of products in biologics, spinal hardware, and orthopedic solutions, operating in around 68 countries globally, with a focus on innovation and education.
Orthofix Medical (NASDAQ:OFIX) will present at the Canaccord Genuity 2023 Musculoskeletal Conference in Las Vegas on March 7, 2023, at 2:00 p.m. PT. Interested parties can access the webcast on the Orthofix Investor Relations website.
This follows the company’s merger with SeaSpine on January 5, 2023, creating a leading global spine and orthopedics entity with a broad product portfolio operating in approximately 68 countries. The new name for the combined entity will be announced later, but it will continue to operate as Orthofix until then.
Orthofix Medical Inc. (NASDAQ:OFIX) announced it will release its fourth quarter 2022 financial results for both Orthofix and SeaSpine, following their merger on January 5, 2023. The results will be disclosed on March 6, 2023, after market close, with a conference call scheduled at 4:30 p.m. ET the same day. The newly merged company positions itself as a leader in spine and orthopedics, distributing products across approximately 68 countries. The combined entity offers a comprehensive portfolio that includes biologics, spinal hardware, and surgical navigation systems, supported by its extensive global operations.
Orthofix Medical Inc (NASDAQ: OFIX) has announced the full commercial launch of the Mariner® Deformity Pedicle Screw System, the first product introduced after its merger with SeaSpine. This system is designed for complex adult deformity spine cases, featuring advanced instrumentation, specialized implant technologies, and robust osteotomy tools. The Mariner Deformity System aims to enhance surgical workflows and reduce costs associated with sterile processing. The combined company operates globally, distributing products in around 68 countries, focusing on innovation in spine and orthopedic markets.
The merger between Orthofix Medical and SeaSpine Holdings became effective on January 5, 2023. Preliminary net sales for SeaSpine in Q4 2022 reached $63.2-$63.7 million, up over 13% year-over-year, while Orthofix reported $122.2 million, reflecting a 2% decline. SeaSpine saw strong growth in U.S. Spinal Implants and Orthobiologics, with increases over 23% and 19%, respectively. In contrast, Orthofix's Spinal Implants revenue declined over 7%. The merger aims to integrate both businesses to leverage synergies and enhance innovation in spine and orthopedic solutions.
Orthofix Medical and SeaSpine Holdings have successfully completed their merger of equals, following stockholder approval. Approximately 99% of SeaSpine voters and 98% of Orthofix voters approved the merger. The merger will be effective from 12:01 AM EST on January 5, 2023, with SeaSpine becoming a wholly-owned subsidiary of Orthofix. SeaSpine shares will cease trading, and shareholders will receive 0.4163 shares of Orthofix for each SeaSpine share. The newly combined company will focus on global spine and orthopedic solutions, and will operate under the Orthofix name.
Orthofix Medical Inc. (NASDAQ: OFIX) announced promising results from a multicenter clinical study on its Trinity Elite cellular bone allograft for lumbar spinal fusion. The study reported a remarkable 98.6% fusion rate at 12 months, as per the published data in Neurology International. The findings highlight significant improvements in patient outcomes, despite various risk factors. Orthofix emphasizes its commitment to clinical research, asserting that Trinity Elite is a safe and effective alternative to traditional autografts, enhancing surgical efficiency and patient recovery.
Orthofix (NASDAQ: OFIX) and SeaSpine (NASDAQ: SPNE) announced the appointment of John Bostjancic as Chief Financial Officer for the merged company, effective upon merger completion. Bostjancic has been CFO of SeaSpine since 2015, with prior experience at Integra Life Sciences. Doug Rice, current CFO of Orthofix, will assist during the transition. The all-stock merger agreement, announced on October 11, 2022, is expected to close in Q1 2023, pending shareholder approvals and customary conditions.